Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
July 18 2024 - 9:00AM
Houston, Texas and Tuebingen, Germany, July
18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a
clinical-stage biopharmaceutical company active in the discovery
and development of T cell-redirecting cancer immunotherapies, today
announced that the first proof-of-concept clinical data for its
next-generation, half-life extended TCR Bispecific molecule, TCER®
IMA401 (MAGEA4/8), will be presented during an oral presentation at
the European Society for Medical Oncology (ESMO) Congress 2024 on
Monday, September 16, 2024 at 11:25 CEST.
Full abstracts will be available on the ESMO
website on Monday, September 9, 2024, at 00:05 CEST.
Oral presentation
Date / Time: September 16, 2024
/ 11:25 CESTSession: Investigational
ImmunotherapyTitle: Initial safety,
pharmacokinetics, and anti-tumor activity data of TCER IMA401, a
MAGEA4/8-directed half-life extended TCR Bispecific, in Phase 1
dose escalationPresenting author: Martin Wermke,
MD (University Hospital Dresden, Germany)Room:
Granada Auditorium - Hall 6
About IMA401
IMA401 is Immatics’ most advanced TCER® molecule
that targets an HLA-A*02-presented (human leukocyte antigen)
peptide derived from two different cancer-associated proteins,
melanoma-associated antigen 4 and/or 8 (“MAGEA4/8”). The MAGEA4/8
peptide has been identified and validated by Immatics’ proprietary
mass spectrometry-based target discovery platform XPRESIDENT® and
is presented at a 5-fold higher copy number per tumor cell than the
MAGEA4 peptide targeted in other clinical trials. Following
preclinical proof-of-concept data, including complete remissions of
transplanted human-derived tumors in xenograft mouse models, the
Phase 1 trial investigates IMA401 in patients with tumors of high
MAGEA4/8 prevalence, such as squamous non-small cell lung carcinoma
(sqNSCLC), small cell lung cancer (SCLC), head and neck squamous
cell carcinoma (HNSCC), bladder, uterine, esophageal and ovarian
carcinomas, as well as melanoma, sarcoma subtypes and other solid
cancer types.
About TCER®
Immatics’ next-generation half-life extended TCER® molecules are
antibody-like “off-the-shelf” biologics that leverage the body’s
immune system by redirecting and activating T cells towards cancer
cells expressing a specific tumor target. The design of the TCER®
molecules enables the activation of any T cell in the body to
attack the tumor, regardless of the T cells’ intrinsic specificity.
Immatics proprietary biologics are engineered with two binding
regions: a TCR domain and a T cell recruiter domain. The TCER®
format is designed to maximize efficacy while minimizing toxicities
in patients. It contains a high-affinity TCR domain that is
designed to bind specifically to the cancer target peptide on the
cell surface presented by an HLA molecule. The antibody-derived,
low-affinity T cell recruiter domain is directed against the
TCR/CD3 complex and recruits a patient’s T cells to the tumor to
attack the cancer cells. With a low-affinity recruiter aiming for
optimized biodistribution and enrichment of the molecule at the
tumor site instead of the periphery, TCER® are engineered to reduce
the occurrence of immune-related adverse events, such as cytokine
release syndrome. In addition, the TCER® format consists of an
Fc-part conferring half-life extension, stability, and
manufacturability. TCER® are “off-the-shelf” biologics and thus
immediately available for patient treatment. They can be
distributed through standard pharmaceutical supply chains and
provide the opportunity to reach a large patient population without
the need for specialized medical centers.
About ImmaticsImmatics combines
the discovery of true targets for cancer immunotherapies with the
development of the right T cell receptors with the goal of enabling
a robust and specific T cell response against these targets. This
deep know-how is the foundation for our pipeline of Adoptive Cell
Therapies and TCR Bispecifics as well as our partnerships with
global leaders in the pharmaceutical industry. We are committed to
delivering the power of T cells and to unlocking new avenues for
patients in their fight against cancer.
Immatics intends to use its website
www.immatics.com as a means of disclosing material non-public
information. For regular updates you can also follow us on X,
Instagram and LinkedIn.
For more information, please contact:
Media |
|
Trophic Communications |
|
Phone: +49 171 3512733 |
|
immatics@trophic.eu |
|
Immatics N.V. |
|
Jordan Silverstein |
|
Head of Strategy |
|
Phone: +1 346 319-3325 |
|
InvestorRelations@immatics.com |
|
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Aug 2023 to Aug 2024